Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Colchicine"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringColchicine
brandStringColcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular)
structureFile
classesList of String, delimiter: ,[[:Category:Antigout_agents|Antigout agent]] [[:Category:Anti-inflammatories|Anti-inflammatory]] [[:Category:Microtubule_inhibitors|Microtubule inhibitor]]
mechanismString
usesString'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"'
starting_doseStringAcute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction
preparationsString0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco)
fda_maxString1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors
pill_idText
routesList of String, delimiter: ,Oral (IV form withdrawn US 2009 due to fatal toxicity reports)
onsetStringAnti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed
durationStringHours per dose
halflifeString~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"'
bioavailabilityString~45% (oral)'"`UNIQ--ref-00000C73-QINU`"'
pregnancyStringUsed in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US